WuXi AppTec

We are excited to announce that our new Munich site at the Life Science Center in Gräfelfing is now open, marking a key step forward in strengthening our CRDMO platform.   Located in the heart of the Munich biotech cluster, the new facility expands our structure-based drug discovery and lab testing capabilities – housing them under one roof. This will enhance our services to better support our customers in Europe and beyond.   Strong synergy across our sites enables innovation and collaboration, helping deliver more groundbreaking therapies to patients who need it most.   #Innovation #LifeSciences

We're delighted to announce that WuXi AppTec has been included in the #FTSE4Good Index Series for the second consecutive year!    This recognition demonstrates our exceptional performance in environmental, social, and governance (#ESG) practices driven by our commitment to advancing #sustainability and enabling #innovation for a healthier world. An independent assessment by FTSE Russell, An LSEG Business, a global index and data provider, scored WuXi AppTec above global industry standards.   Through our unique CRDMO and CTDMO business models, we continue to support customers’ needs by developing and delivering innovative new therapies to patients worldwide, working together towards a better and more sustainable future.

At WuXi STA, we foster an environment where diverse talents harmonize scientific excellence with creative thinking to drive #healthcare #breakthroughs. Analytical scientist Lena Ghadimipour, M.Sc thrives in this innovative culture at our San Diego site. Her collaborative team pushes boundaries together, united by a shared mission to accelerate life-changing treatments to patients worldwide. WuXi STA celebrates talents like Lena who blend passion and ingenuity to overcome complex challenges. Join us on this journey of healthcare innovation, fueled by curiosity and teamwork! https://lnkd.in/e2UeJY-d #WuXiSTASanDiego #Teamwork #Pharmaceuticals #TalentCelebration

At WuXi AppTec, our goals are rooted in our core values: doing the right thing and doing it right. We harness science and innovation not just for health advancements but also to safeguard our environment. Through minimizing our carbon footprint and adopting green practices, we embed sustainability in all we do.    On #WorldEnvironmentDay, we stand with the world to honor our planet and reinforce our dedication to environmental #sustainability.

WuXi AppTec, one of the world’s leading pharmaceutical Contract Research, Development and Manufacturing Organisations (CRDMO), has broken ground on a new facility in Singapore. The new CRDMO campus will expand WuXi AppTec’s offerings to its #pharmaceutical and #lifescience customers seeking expanded flexibility and scalability. Once it is fully operational, the facility is expected to provide approximately 1,600 employment opportunities in Singapore. As part of the CRDMO campus, WuXi AppTec will set up its Green Chemistry Centre of Excellence (CoE) for Drug Manufacturing. The CoE will focus on sustainable drug production and spearhead technologies around more efficient and environmentally friendly drug manufacturing processes. In addition, the company will also introduce its WuXi TIDES platform at the Singapore site to drive the development of peptide and oligonucleotide drugs, which are a new generation of targeted treatments. This will dovetail with Singapore’s efforts to build up capabilities in precision medicine, under our Research, Innovation and Enterprise (RIE) 2025 plan. Read about how WuXi AppTec’s new facility in #Singapore will help its customers around the world accelerate the development and commercialisation of life-saving therapies: https://lnkd.in/gxu3VS4z

Folks, In these complex times, clarity and truth are more important than ever. The reality is that legislation being considered in Congress would negatively impact industry innovation and upend the delivery of critical treatments to patients in need. Get the facts: https://lnkd.in/eViYEskV 

Our #philadelphia site has been approved by the U.S. #FDA to begin the analytical testing and manufacturing of #Amtagvi for Iovance Biotherapeutics, Inc., which received an accelerated approval of its Biologics License Application (#BLA) on February 16, 2024.  Congratulations to Iovance Biotherapeutics, Inc. on this major milestone! With this announcement, our site at the Navy Yard in Philadelphia becomes the first U.S. external manufacturing site and the first third-party #CTDMO to be approved to support the commercial manufacturing and release of an individualized T cell therapy for a solid tumor cancer.  We are thrilled to help through each step of the drug development pipeline – from research to clinical manufacturing to approval and we are proud to partner with healthcare innovators to advance medical discoveries and deliver groundbreaking treatments to patients globally.   https://lnkd.in/duTPi9TA   #celltherapy #tcells

🙌 A big thank you to all who joined us yesterday for our digital #WuXiGlobalForum! In case you missed it, subscribe to our newsletter for insights into our BOLD online series, highlighting influential global thought leaders #TakingBOLDAction in the healthcare industry by: ✅ Breaking Barriers ✅ Opening New Horizons ✅ Leading Next Generation ✅ Delivering for Patients Signup here: https://lnkd.in/gsYmcC9u

Exciting progress! WuXi STA, a subsidiary of WuXi AppTec announced the launch of its new Blow-Fill-Seal (#BFS) aseptic filling line at the Wuxi City site! This expansion aligns with our continuous efforts to strengthen #CRDMO platform capabilities, empowering our global partners to accelerate more innovative therapies for patients worldwide. Stay tuned for more updates! #Innovation #Healthcare

🎥 Tune in on WEDNESDAY at 7 AM or 7 PM PST to see prominent industry experts cover our industry's progress and the path toward catalyzing change for patients. Don't miss out on the digital #WuXiGlobalForum! https://lnkd.in/geY5pHqp